'Gold standard' continues to shine in medicine

Monday, October 14, 2019
Charlie Butts (OneNewsNow.com)

microsurgeryUse of adult stem cells continues to prove valuable in treating serious medical conditions.

The adult stem cells, which can be obtained readily from the human body, have now been successful in treating and reversing Neuromyelitis optica (NMO), a central nervous system disorder that primarily affects the eye nerves (optic neuritis) and the spinal cord (myelitis).

Usually within a few years, more than half of the patients who treat the disorder with drugs go blind and cannot walk. But Dr. David Prentice of the Charlotte Lozier Institute tells OneNewsNow Dr. Richard Burt of Northwestern University has used adult stem cells to successfully treat a dozen patients with the condition.

"10 of the 12 patients five years after a single treatment with adult stem cells are still without any need for any drugs or any kind of treatment," Dr. Prentice reports.


So two of the patients had to return to drug treatment, but ten are in remission. The study was published in the Neurology journal.

"This is just another evidence that adult stem cells are the gold standard for stem cells, now treating over two million patients around the globe for dozens of different conditions," says Dr. Prentice.

Charlotte Lozier Institute profiles this case and many others like it, and research with human embryos has yet to produce any success in treating medical conditions.


We moderate all reader comments, usually within 24 hours of posting (longer on weekends). Please limit your comment to 300 words or less and ensure it addresses the article - NOT another reader's comments. Comments that contain a link (URL), an inordinate number of words in ALL CAPS, rude remarks directed at other readers, or profanity/vulgarity will not be approved. More details
Information is power – and 'big tech' has both

technology (generic)The major technology companies could have more national security data than the federal government, according to a panel of experts at The Heritage Foundation.